Kristian Reich

Company: MoonLake Immunotherapeutics

Job title: Chief Scientific Officer

Seminars:

Expanding the Role of the IL-17A & IL-17F inhibiting Nanobody® Sonelokimab Across Derm & Rheum Indications – Data from a Global Placebo- & Active Comparator-Controlled Phase 2 Study in Psoriatic Arthritis 12:15 pm

Explore the rapid achievement of high response levels in joints and skin across ACR and PASI thresholds, as well as composite measures such as MDA, shedding light on the dynamics of clinical response patterns Consistent safety results observed in the ARGO and previous sonelokimab trials, emphasising the absence of new safety signals and contributing additional…Read more

day: Day Two